Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 2171.5, up 1.22% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.37% on the day, quoting at 24744.75. The Sensex is at 81052.89, down 0.5%. Glenmark Pharmaceuticals Ltd has added around 23.82% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has added around 3.26% in last one month and is currently quoting at 22662.7, up 0.42% on the day. The volume in the stock stood at 8.1 lakh shares today, compared to the daily average of 21.89 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 2162.6, up 0.63% on the day. Glenmark Pharmaceuticals Ltd is up 50.76% in last one year as compared to a 0.37% fall in NIFTY and a 4.99% fall in the Nifty Pharma index.
The PE of the stock is 34.69 based on TTM earnings ending March 25.
Glenmark Pharmaceuticals Ltd rose for a fifth straight session today. The stock is quoting at Rs 2235, up 0.4% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.03% on the day, quoting at 25204.3. The Sensex is at 82632.7, up 0.07%. Glenmark Pharmaceuticals Ltd has added around 35.19% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has added around 4.6% in last one month and is currently quoting at 22665.7, down 0.21% on the day. The volume in the stock stood at 7.39 lakh shares today, compared to the daily average of 20.14 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 2245, up 0.74% on the day. Glenmark Pharmaceuticals Ltd is up 58.13% in last one year as compared to a 1.63% gain in NIFTY and a 8.9% gain in the Nifty Pharma index.
The PE of the stock is 36.03 based on TTM earnings ending March 25.
In an official filing, the company stated that it does not anticipate the warning letter will disrupt supply chains or affect revenues generated from the Indore facility. Glenmark emphasized its commitment to addressing the FDA’s concerns promptly and working closely with the regulator to resolve the issues.
The company further clarified that there were no observations related to data integrity during the inspection. Glenmark reaffirmed its dedication to maintaining the highest quality and compliance standards, including adherence to Current Good Manufacturing Practices (CGMP), across all its facilities.
Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.
On a consolidated basis, Glenmark Pharmaceuticals reported a net profit of Rs 4.65 crore in Q4 March 2025 as against a net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025.
The scrip shed 0.56% to Rs 2,169.30 on the BSE.
Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 2214.7, up 1.54% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 25050.1. The Sensex is at 82139.43, down 0.44%. Glenmark Pharmaceuticals Ltd has gained around 31.56% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 2% in last one month and is currently quoting at 22225.9, up 1.15% on the day. The volume in the stock stood at 27.13 lakh shares today, compared to the daily average of 18.89 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 2223, up 1.92% on the day. Glenmark Pharmaceuticals Ltd is up 57.28% in last one year as compared to a 1.88% jump in NIFTY and a 7.85% jump in the Nifty Pharma index.
The PE of the stock is 35.29 based on TTM earnings ending March 25.